Mineralys Therapeutics, Inc. MLYS Tax Credit Carryforward Valuation Allowance
Tax Credit Carryforward Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s tax credit carryforward valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s tax credit carryforward valuation allowance?
- Mineralys Therapeutics, Inc. (MLYS) reported tax credit carryforward valuation allowance of $121.25M in Q4 2025.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s tax credit carryforward valuation allowance?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s tax credit carryforward valuation allowance has grown at a 111.0% compound annual growth rate (CAGR), from $12.92M to $121.25M.
- What does tax credit carryforward valuation allowance mean?
- This is a contra-asset account that reduces the carrying value of tax credit carryforwards when it is more likely than not that some or all of the credits will not be realized. It reflects management's assessment of the company's ability to generate sufficient future taxable income. A high allowance suggests uncertainty regarding the realization of tax benefits.